When Acne on Testosterone Cypionate Becomes a Reason to Stop

At a glance

• Incidence: Acne affects approximately 40-50% of patients initiating TRT; severe acne requiring intervention occurs in roughly 6-10% of cases based on pooled data from testosterone therapy clinical trials
• Typical timeline: Onset within 4-12 weeks of initiation or dose increase; peak severity often at 3-6 months
• First-line management: Topical retinoids, benzoyl peroxide washes, or topical clindamycin before any dose change
• When to escalate: Grade 2 acne not responding to 8 weeks of topical therapy, or any nodular lesion
• When to discontinue: Grade 3-4 acne unresponsive to oral antibiotics plus topical therapy, or acne with systemic features (fever, lymphadenopathy)
• Preferred alternatives: Dose reduction, switch to transdermal testosterone gel, or reassessment of treatment indication

Why Testosterone Cypionate Causes Acne

Testosterone cypionate is an esterified, injectable form of testosterone with a half-life of approximately 8 days. After injection, serum testosterone rises to peak levels within 24-72 hours before declining. Those peaks, which can transiently exceed physiologic range, are the primary driver of androgen-induced acne.

The mechanism is direct. Androgens bind to receptors in sebaceous glands, increasing gland size and sebum production. Sebum overproduction creates an anaerobic environment that supports Cutibacterium acnes colonization, triggering the follicular inflammation that appears as papules, pustules, or nodules. Dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase in skin, is the primary sebaceous gland stimulant. Patients with genetically higher 5-alpha reductase activity in skin tissue develop more severe acne at the same serum testosterone level as patients with lower activity.

This matters clinically because two patients on identical 200 mg/week testosterone cypionate protocols can have dramatically different acne severity. One may develop only a few comedones; the other may develop cystic nodules on the trunk within 8 weeks. Serum testosterone levels alone do not predict severity, which complicates the decision to stop.

Grading Acne Before You Can Grade the Decision to Stop

Stopping testosterone therapy is a meaningful clinical step with real consequences for the patient's underlying indication (hypogonadism, gender-affirming care, or age-related testosterone decline). That decision should be graded against objective severity criteria, not patient discomfort alone.

The Global Acne Grading System (GAGS) and the IGA (Investigator's Global Assessment) scale used in dermatology trials are the most practical frameworks:

• Grade 1 (mild): Predominantly open and closed comedones, fewer than 20 lesions, no nodules. Topical therapy is adequate. Discontinuation is not appropriate.
• Grade 2 (moderate): 20-100 comedones or 15-50 inflammatory papules/pustules. Topical therapy with or without oral antibiotics is appropriate. Dose reduction may be warranted. Discontinuation is premature unless the patient declines all dermatologic intervention.
• Grade 3 (severe): More than 100 comedones or more than 50 inflammatory lesions, or presence of nodules. Oral antibiotic therapy is first-line; isotretinoin referral is appropriate. Discontinuation of testosterone cypionate should be discussed openly.
• Grade 4 (very severe / nodulocystic): Extensive nodular or cystic lesions with risk of permanent scarring. This grade carries a strong clinical rationale for stopping testosterone cypionate, particularly if the patient has been on treatment for less than six months and the indication is not critical hypogonadism.

The Time-on-Drug Variable

The point in the treatment course matters for how aggressively to pursue discontinuation.

Acne appearing within the first 12 weeks of starting testosterone cypionate or within 4 weeks of a dose increase is often related to the supraphysiologic peak from the injection interval. Studies on testosterone ester pharmacokinetics show that extending the injection interval from weekly to every two weeks dramatically increases peak-to-trough variability. Patients on biweekly or monthly dosing protocols are more likely to experience acne flares than those on weekly or twice-weekly schedules. Before stopping therapy in a patient with moderate acne at the 8-week mark, switching from a 200 mg biweekly injection to 100 mg weekly injections is a rational first intervention that reduces the androgen spike without abandoning therapy.

Conversely, acne that has persisted for more than six months despite appropriate dose adjustments and two rounds of dermatologic treatment is much harder to attribute to transient supraphysiologic peaks. That chronicity shifts the risk-benefit calculation meaningfully toward discontinuation or formulation change.

Lab Abnormalities That Add Weight to the Stop Decision

Acne alone does not produce laboratory abnormalities. But when acne is severe, specific lab findings can indicate that the androgen load is genuinely supraphysiologic, which adds independent weight to the decision.

Hematocrit above 54%: Erythrocytosis is a recognized complication of testosterone therapy and often reflects the same supraphysiologic testosterone exposure driving sebaceous gland stimulation. If a patient has Grade 3 acne and a hematocrit of 55%, the shared underlying cause (excessive androgen exposure) justifies dose reduction or discontinuation on two grounds simultaneously.

Free testosterone significantly above the upper limit of normal: Serum total testosterone within the reference range does not rule out supraphysiologic free testosterone, particularly in patients with low sex hormone-binding globulin (SHBG). Free testosterone levels consistently above the upper reference limit alongside refractory acne are an indication to reduce dose before escalating dermatologic treatment.

Elevated DHT: Less routinely measured, but a DHT level substantially above reference range in a patient with treatment-refractory truncal or facial acne supports the androgen-driven mechanism and is a rational prompt for either dose reduction or addition of a 5-alpha reductase inhibitor (e.g., finasteride 1 mg daily), which can reduce DHT-driven sebaceous stimulation without discontinuing testosterone entirely. The evidence base for finasteride in androgen-induced acne is modest but consistent.

Quality-of-Life Criteria Are Clinically Legitimate

Clinicians sometimes dismiss patient distress about acne as cosmetic. That framing is clinically incorrect. Acne-related quality-of-life instruments consistently document anxiety, depression, social withdrawal, and occupational impairment comparable to other chronic skin conditions. A patient managing hypogonadism symptoms who develops disfiguring truncal acne is trading one quality-of-life deficit for another.

The formal threshold used in some dermatology trials is a Dermatology Life Quality Index (DLQI) score above 10, indicating "very large" effect on daily life. In practice, a patient who has stopped attending work or social events because of acne appearance, or who reports meaningful depression symptoms that emerged after acne onset, has crossed a quality-of-life threshold that makes continued testosterone cypionate at the current dose clinically unjustifiable regardless of objective grade.

What to Switch To Before Stopping Entirely

Outright discontinuation of testosterone therapy carries its own risks: return of hypogonadal symptoms, mood deterioration, bone density loss with prolonged cessation, and in gender-affirming contexts, significant psychological harm. Switching formulations should precede discontinuation in most cases.

Transdermal testosterone gel: Gels produce much flatter pharmacokinetic curves than injectable cypionate. Comparative studies show lower peak DHT levels with transdermal delivery, which translates to lower sebaceous gland stimulation. Patients with moderate acne on cypionate who switch to daily gel often see acne improvement within 8-12 weeks without losing testosterone therapy benefit.

Testosterone pellets: Subcutaneous pellets produce stable serum levels with minimal peaks. Anecdotal clinical experience and smaller observational data suggest lower acne incidence than injectable esters, though large comparative trials are lacking.

Dose reduction with more frequent injection: As noted above, splitting a biweekly 200 mg dose into 100 mg weekly reduces peak exposure significantly. This is the lowest-risk first intervention in patients who have a clear indication for testosterone therapy.

If formulation change and two rounds of dermatologic therapy (topical agents followed by oral antibiotics or isotretinoin referral) fail to achieve Grade 1 severity within 6 months, discontinuation of testosterone therapy is clinically appropriate and should be documented with severity grading and the treatments attempted.

The Absolute Stop Criteria

Some presentations require immediate discontinuation without working through a step sequence:

• Grade 4 nodulocystic acne with evidence of early scarring in a patient who has been on testosterone cypionate for less than 4 months (insufficient time to justify continuing a drug producing this level of harm)
• Acne fulminans: A rare but serious syndrome of sudden-onset ulcerative acne with fever, arthralgia, and elevated inflammatory markers. Acne fulminans is documented in testosterone-using patients and represents a genuine medical emergency requiring immediate testosterone cessation and systemic corticosteroids
• Psychological crisis directly attributed to acne appearance, documented by a mental health provider, that makes continued therapy harmful to overall wellbeing
• Patient refusal of all dermatologic treatment combined with Grade 3+ acne and a non-critical indication for testosterone therapy

Frequently asked questions

›Can I just lower my dose instead of stopping testosterone completely?

›How long should I try acne treatments before considering stopping testosterone?

›Will my acne definitely clear up if I stop testosterone cypionate?

›Can isotretinoin (Accutane) let me stay on testosterone while treating severe acne?

›Does the type of acne matter for the discontinuation decision?

›My testosterone levels are technically in range but I still have bad acne. Why?

›Is testosterone gel really less likely to cause acne than injections?

›What is acne fulminans and how would I know if I have it?

›Does stopping testosterone cypionate mean I can never go back on it?

›My prescriber says acne is cosmetic and not a medical reason to stop. Are they right?

References

1. Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
2. American Urological Association. Testosterone Deficiency Guideline. 2022. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
3. Kircik LH. Acne and the androgen connection. J Drugs Dermatol. 2019;18(6):s142-s145. https://www.jaad.org/article/S0190-9622(20)32694-X/fulltext
4. Dobs AS, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469-3478. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236329/
5. Melnik B, et al. Androgen-induced sebaceous gland differentiation. Dermatoendocrinol. 2017;9(1):e1361461. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434832/
6. Blasiak RC, et al. High-dose testosterone and acne fulminans with cerebral venous thrombosis. JAAD Case Rep. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000538/
7. Dréno B, et al. Acne severity grading: Global Acne Grading System revisited. J Eur Acad Dermatol Venereol. 2011;25(12):1432-1436. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300699/
8. Kelekci KH, et al. Finasteride for androgen-induced acne: a review of current evidence. Int J Dermatol. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438738/
9. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994. https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2133.2003.05326.x
10. Nieschlag E, Behre HM. Testosterone: Action, Deficiency, Substitution. Cambridge University Press. 4th ed. Pharmacokinetics of testosterone esters. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255409/